Table 3 Treatment-emergent adverse events occurring in ≥ 1.5% patients in the galcanezumab group
Preferred term, n (%) | Galcanezumab 120 mg (N = 261) | Placebo (N = 259) |
|---|---|---|
Patients with ≥ 1 TEAE | 130 (49.8) | 112 (43.2) |
Injection site pain | 19 (7.3) | 16 (6.2) |
Upper respiratory tract infection | 14 (5.4) | 13 (5.0) |
Injection site pruritis | 13 (5.0) | 0 |
Injection site reaction | 10 (3.8) | 1 (0.4) |
Dizziness | 9 (3.4) | 6 (2.3) |
Nasopharyngitis | 7 (2.7) | 9 (3.5) |
Injection site discomfort | 6 (2.3) | 0 |
Protein urine present | 6 (2.3) | 4 (1.5) |
Pyrexia | 6 (2.3) | 3 (1.2) |
Abdominal discomfort | 5 (1.9) | 2 (0.8) |
Aspartate aminotransferase increased | 5 (1.9) | 0 |
Injection site erythema | 5 (1.9) | 0 |
Alanine aminotransferase increased | 4 (1.5) | 0 |
Blood creatinine phosphokinase increased | 4 (1.5) | 0 |
Diarrhea | 4 (1.5) | 6 (2.3) |
Pruritis | 4 (1.5) | 2 (0.8) |